BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 29, 2026
Home » Blogs » BioWorld Perspectives » Cancer Research Through Time: Cure Should’ve Been Wrapped up by 1985

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Cancer Research Through Time: Cure Should’ve Been Wrapped up by 1985

April 8, 2013
By Anette Breindl

If you’re looking for a plenary speaker, pick a Pulitzer Prize winner. That was one of the corollary lessons to be had from the talk of Columbia University’s Siddhartha Mukherjee at the American Association for Cancer Research’s Annual Meeting on Sunday, which was somewhat like a Cliff Notes version of his Pulitzer-Prize winning epic on cancer, “The Emperor of all Maladies.”

Mukherjee regaled the audience with an apocryphal tale of a historian who was asked to predict the future of the Soviet Union and answered that “in the Soviet Union, the future is quite easy to predict. The problem is the past. The past keeps changing.”

That problem, he said, is also one in cancer research – faced with a cancer cell, we have ever-changing notions of how it got to be that way. Mukherjee traced the dominant theory of cancer’s natural history from the 1860s, when Rudolf Virchow first argued that dysregulated cell division is the root cause of cancer, to the notion now taking root that cancer is an organismal disease that involves changes to the microenvironment and the immune system of the cancer patient as well as to the genes and genomes that make up the cancerous cells.

Along the way, he shared fascinating stories of cancer and its treatments. The first chemotherapy was a chemical cousin of notorious World War I weapon mustard gas; pioneering surgeon and Johns Hopkins University co-founder William Halsted was addicted to both cocaine and morphine, which in his day was used to treat cocaine addiction; in the 1960s, philanthropist and medical research champion Mary Lasker thought that the cancer problem would be wrapped up by 1985.

At BioWorld, we’ve recommended The Emperor of all Maladies before, of course. It’s too much in our sweet spot not to. But good advice never gets old, and so if you have not read the book, it is still worth heading to your local bookstore, or library, and picking up a copy.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 28, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing